A carregar...
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 o...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6935287/ https://ncbi.nlm.nih.gov/pubmed/31920387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S212559 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|